The reversible, dual EGFR and HER2 tyrosine kinase inhibitor, lapatinib, has showed certain activity in cell lines, but this is not clinically relevant in patients with NSCLC (13,14). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.